Filtering by Category: diagnostics
Researchers at Queens University Belfast have published findings where a multi-marker panel of 4 proteins (CA125, phosphatidylcholine-sterol aceltransferase, vitamin K-dependent protein Z, and CRP) has the potential to diagnose epithelial ovarian cancer (EOC) one to two years earlier than current methods.
The SpotProfiler is a prime candidate to translate this type of research finding into an easily accessible medical tool for physicians with its multi-marker protein microarray approach.
San Francisco-based DotLab has raised $10 million in series A funding to continue development of its DotEndo test, a liquid biopsy test that detects disease-specific biomarkers for endometriosis in blood or saliva samples. The test can also be used to track therapy response and recurrence.
Resolution Bioscience's blood test was granted a breakthrough device designation by the FDA in May. It is currently being used to help develop a companion liquid biopsy test for Janssen’s PARP inhibitor Zejula (niraparib) drug in patients with metastatic castration-resistant prostate cancer.
Connecticut-based Tangen has raised $9 million in a series A round to put the company’s TangenDx platform into the clinic in two trials focused on obtaining FDA clearances in diagnosing infectious diseases and commercialize in 2020. TangenDx is a DNA/PCR-based test system that is battery-powered and delivers results in less than one hour.
Abbott launched its new point-of-care diabetes blood test, the Afinion HbA1c Dx test. It can provide hemoglobin A1c results in 3 minutes, allowing clinicians to develop and start care plans within a patient’s single visit to the doctor’s office.
The FDA, the Centers for Disease Control and Prevention and the Centers for Medicare and Medicaid Services in the USA have formed an interagency task force with the goal of facilitating rapid development and deployment of in vitro diagnostic tests during public health emergencies.
Sight Diagnostics received the CE Mark last year for its OLO system, which uses digital microscopy to visually analyze cell types by size, shape, count and morphology, from a few drops of blood during a single office visit. The technology has been used to screen over 600,000 samples for malaria infections and will now be adding complete blood count testing to its system. Sight Diagnostics has raised US$27.8 million to continue its global commercial expansion, fund regulatory efforts and support its research and development.
CellMax Life’s CMx platform filters out and counts precancer and cancer cells in the bloodstream. It’s FirstSightCRC test was able to detect the small, precancerous colon polyps known as adenomas with close to 90% accuracy. The increases in cell counts also correlates with increases in disease severity. This is a highly sensitive noninvasive testing option for precancer instead of a colonoscopy.
Contextual Genomics provides assays for detecting genomic mutations in blood and solid tumours. It has released a new version of its Find It solid tumour panel, while its new Follow It panel screens for the same mutations in cell-free circulating tumour DNA found in blood plasma. Follow It can be used to monitor tumour burden, treatment resistance and disease progression.
Liquid biopsy company, Seer, has received $36 million in funding to develop early-warning tests for cancer and neurological diseases. It uses nanotechnology, protein chemistry and machine learning algorithms to profile a broad array of the body’s proteins and generate insights into the progression of diseases at the population level. Seer hopes to collaborate with industry partners to develop new products using this system.